JP2018510147A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510147A5 JP2018510147A5 JP2017546200A JP2017546200A JP2018510147A5 JP 2018510147 A5 JP2018510147 A5 JP 2018510147A5 JP 2017546200 A JP2017546200 A JP 2017546200A JP 2017546200 A JP2017546200 A JP 2017546200A JP 2018510147 A5 JP2018510147 A5 JP 2018510147A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fully human
- seq
- cancer
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128462P | 2015-03-04 | 2015-03-04 | |
| US62/128,462 | 2015-03-04 | ||
| PCT/US2016/020980 WO2016141328A2 (en) | 2015-03-04 | 2016-03-04 | Antibody therapeutics that bind cd47 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186564A Division JP2020023532A (ja) | 2015-03-04 | 2019-10-10 | Ｃｄ４７に結合する抗体医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510147A JP2018510147A (ja) | 2018-04-12 |
| JP2018510147A5 true JP2018510147A5 (enExample) | 2019-04-04 |
| JP6643350B2 JP6643350B2 (ja) | 2020-02-12 |
Family
ID=56848772
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546200A Active JP6643350B2 (ja) | 2015-03-04 | 2016-03-04 | Ｃｄ４７に結合する抗体医薬 |
| JP2019186564A Withdrawn JP2020023532A (ja) | 2015-03-04 | 2019-10-10 | Ｃｄ４７に結合する抗体医薬 |
| JP2021000870A Active JP7137646B2 (ja) | 2015-03-04 | 2021-01-06 | Ｃｄ４７に結合する抗体医薬 |
| JP2021000869A Active JP7105938B2 (ja) | 2015-03-04 | 2021-01-06 | Ｃｄ４７に結合する抗体医薬 |
| JP2021089081A Withdrawn JP2021121635A (ja) | 2015-03-04 | 2021-05-27 | Ｃｄ４７に結合する抗体医薬 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186564A Withdrawn JP2020023532A (ja) | 2015-03-04 | 2019-10-10 | Ｃｄ４７に結合する抗体医薬 |
| JP2021000870A Active JP7137646B2 (ja) | 2015-03-04 | 2021-01-06 | Ｃｄ４７に結合する抗体医薬 |
| JP2021000869A Active JP7105938B2 (ja) | 2015-03-04 | 2021-01-06 | Ｃｄ４７に結合する抗体医薬 |
| JP2021089081A Withdrawn JP2021121635A (ja) | 2015-03-04 | 2021-05-27 | Ｃｄ４７に結合する抗体医薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10035855B2 (enExample) |
| EP (1) | EP3265125A4 (enExample) |
| JP (5) | JP6643350B2 (enExample) |
| KR (2) | KR102625835B1 (enExample) |
| CN (2) | CN114380912B (enExample) |
| AR (1) | AR103868A1 (enExample) |
| AU (2) | AU2016225993B2 (enExample) |
| IL (2) | IL254321B (enExample) |
| MX (1) | MX385673B (enExample) |
| TW (3) | TWI843184B (enExample) |
| WO (1) | WO2016141328A2 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220104298A (ko) | 2016-10-20 | 2022-07-26 | 아이-맵 바이오파마 유에스 리미티드 | 새로운 cd47 단일클론 항체 및 그 용도 |
| US11352425B2 (en) | 2016-11-08 | 2022-06-07 | Absos, Llc | Anti-CD47 antibodies |
| US11267885B2 (en) | 2017-01-26 | 2022-03-08 | Zlip Holding Limited | CD47 antigen binding unit and uses thereof |
| US11286301B2 (en) | 2017-02-28 | 2022-03-29 | The Board Of Trustees Of The Leland Stanford Junior University | Antifibrotic activity of CD47 blockade |
| AU2018312222B2 (en) | 2017-08-02 | 2024-11-21 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| WO2019095358A1 (zh) * | 2017-11-20 | 2019-05-23 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
| CA3083946A1 (en) | 2017-12-01 | 2019-06-06 | Seattle Genetics, Inc. | Cd47 antibodies and uses thereof for treating cancer |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| WO2020009725A1 (en) * | 2018-07-05 | 2020-01-09 | Trican Biotechnology Co., Ltd | Human anti-cd47 antibodies and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CA3107369A1 (en) * | 2018-10-31 | 2020-05-07 | I-Mab Biopharma Us Limited | Novel cd47 antibodies and methods of using same |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| US20210147568A1 (en) | 2019-10-31 | 2021-05-20 | Forty Seven, Inc. | Anti-cd47 based treatment of blood cancer |
| WO2021113596A2 (en) | 2019-12-05 | 2021-06-10 | Sorrento Therapeutics, Inc. | Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| CN113004406B (zh) * | 2019-12-20 | 2022-04-26 | 广东菲鹏制药股份有限公司 | 抗cd47抗体及其应用 |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| EP4171617A1 (en) | 2020-06-30 | 2023-05-03 | Mendus B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| WO2022022662A1 (zh) * | 2020-07-31 | 2022-02-03 | 百奥泰生物制药股份有限公司 | Cd47抗体及其应用 |
| WO2022109227A1 (en) * | 2020-11-19 | 2022-05-27 | Icahn School Of Medicine At Mount Sinai | Combined cancer therapy of b7-h3 and cd47 immune checkpoint inhbitior and methods of use |
| KR102757518B1 (ko) * | 2020-12-07 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
| EP4274853A4 (en) * | 2021-01-05 | 2024-12-04 | National Institute Of Biological Sciences, Beijing | BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47 |
| US20220305100A1 (en) | 2021-03-12 | 2022-09-29 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CN117279948A (zh) | 2021-05-07 | 2023-12-22 | 益免安协公司 | 与cd47和pd-l1特异性结合的双特异性抗体 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117881698A (zh) * | 2021-06-30 | 2024-04-12 | 创新生物有限公司 | 对cd47具有特异性的人源化抗体及包含其的用于预防或治疗cd47相关疾病的药物组合物 |
| KR20240091056A (ko) | 2021-10-28 | 2024-06-21 | 길리애드 사이언시즈, 인코포레이티드 | 피리디진-3(2h)-온 유도체 |
| WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
| KR102438419B1 (ko) * | 2021-12-01 | 2022-09-01 | 메디포스트(주) | Cd47 과발현 중간엽 줄기세포를 포함하는 폐 질환 예방 또는 치료용 조성물 |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2024545193A (ja) | 2021-12-22 | 2024-12-05 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| US12358887B2 (en) | 2022-03-17 | 2025-07-15 | Gilead Sciences, Inc. | IKAROS Zinc Finger Family degraders and uses thereof |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN119487038A (zh) | 2022-04-21 | 2025-02-18 | 吉利德科学公司 | Kras g12d调节化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| KR102891091B1 (ko) * | 2024-05-22 | 2025-11-27 | 주식회사 이뮨온시아 | 항-cd47 항체를 이용한 진행성 또는 전이성 고형암의 치료 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138496B2 (en) * | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| EP2111869A1 (en) * | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| ES2616010T3 (es) * | 2010-05-14 | 2017-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Anticuerpos monoclonales humanizados y quiméricos a CD47 |
| HRP20191500T1 (hr) * | 2012-02-06 | 2019-11-29 | Inhibrx Inc | Protutijela protiv cd47 i postupci njihove upotrebe |
| LT2900694T (lt) * | 2012-09-27 | 2018-11-12 | Merus N.V. | Bispecifiniai igg antikūnai kaip t ląstelių aktyvatoriai |
| EP2925782B1 (en) * | 2012-12-03 | 2020-01-22 | NovImmune SA | Anti-cd47 antibodies and methods of use thereof |
| RU2015122228A (ru) * | 2012-12-12 | 2017-01-19 | Васкулокс Инк. | Терапевтические антитела к CD47 |
| BR112015018851A2 (pt) * | 2013-02-06 | 2017-07-18 | Inhibrx Llc | anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos |
-
2016
- 2016-03-04 WO PCT/US2016/020980 patent/WO2016141328A2/en not_active Ceased
- 2016-03-04 MX MX2017011329A patent/MX385673B/es unknown
- 2016-03-04 TW TW111131339A patent/TWI843184B/zh active
- 2016-03-04 AR ARP160100592A patent/AR103868A1/es unknown
- 2016-03-04 TW TW105106782A patent/TWI719966B/zh active
- 2016-03-04 US US15/061,771 patent/US10035855B2/en active Active
- 2016-03-04 JP JP2017546200A patent/JP6643350B2/ja active Active
- 2016-03-04 CN CN202210050901.6A patent/CN114380912B/zh active Active
- 2016-03-04 KR KR1020177028115A patent/KR102625835B1/ko active Active
- 2016-03-04 AU AU2016225993A patent/AU2016225993B2/en active Active
- 2016-03-04 EP EP16759606.3A patent/EP3265125A4/en active Pending
- 2016-03-04 KR KR1020247000720A patent/KR102850868B1/ko active Active
- 2016-03-04 CN CN201680024600.9A patent/CN107921121B/zh active Active
- 2016-03-04 TW TW110105132A patent/TWI778518B/zh active
-
2017
- 2017-09-04 IL IL254321A patent/IL254321B/en unknown
-
2019
- 2019-10-10 JP JP2019186564A patent/JP2020023532A/ja not_active Withdrawn
-
2020
- 2020-12-21 AU AU2020294159A patent/AU2020294159B2/en active Active
-
2021
- 2021-01-06 JP JP2021000870A patent/JP7137646B2/ja active Active
- 2021-01-06 JP JP2021000869A patent/JP7105938B2/ja active Active
- 2021-05-27 JP JP2021089081A patent/JP2021121635A/ja not_active Withdrawn
- 2021-11-09 IL IL287958A patent/IL287958B2/en unknown